Full-Time
Posted on 6/23/2025
Therapies for Type 2 Diabetes
No salary listed
Mid, Senior
Burlington, MA, USA
In Person
Fractyl Health focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy platform aimed at improving the function of pancreatic islet cells, which are essential for regulating blood sugar levels. By enhancing these cells, Fractyl seeks to achieve long-term remission for patients with T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still undergoing FDA oversight. Unlike many competitors, Fractyl's approach centers on gene therapy to address the underlying issues of these conditions rather than just managing symptoms. The company's goal is to develop transformative therapies that can prevent and eliminate T2D and obesity, ultimately improving patient health outcomes.
Company Size
51-200
Company Stage
IPO
Headquarters
Lexington, Kentucky
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.
Fractyl is also working on a gene therapy platform called Rejuva.
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET.A live webcast of the conference call can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 5:00 p.m. PT (8:00 p.m. ET).A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at https://ir.fractyl.com/
Conservest Capital Advisors Inc. makes new $132,000 investment in Fractyl Health, Inc. (NASDAQ:GUTS).
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita(R) in patients with T2D in Germany